Fate Therapeutics
FATE
16 hedge funds and large institutions have $24.7M invested in Fate Therapeutics in 2013 Q4 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
19.23% more ownership
Funds ownership: 0% → 19.23% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.54M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$5.43M |
| 3 |
O
OrbiMed
New York
|
+$4.42M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.43M |
| 5 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$1.91M |
Top Sellers
FATE Hedge Fund Activity: Q4 2013 in Review
16 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2013, worth a combined $24.7M.
Buyers outnumbered sellers: 16 funds opened new FATE positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $7.54M.
- 16 institutional investors held Fate Therapeutics (FATE) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $24.7M of Fate Therapeutics stock for Q4 2013.
- 16 funds opened new Fate Therapeutics positions in Q4 2013 and 0 closed out, a net change of +16 holders.
- The largest Fate Therapeutics buyer in Q4 2013 was Wellington Management Group, an estimated $7.54M added.
Based on aggregated 13F filings for Q4 2013.